skweze, about the marketing.
PPHM has the only upstream and it combines with many oncology and viral drugs, plus the new immune therapies and radio etc.
It will be given by doctors to increase the results of the existing drugs they use in their respective treatments. SOC will have been established with BAVI.
The isn't going to be a big marketing issue, at least not the type of efforts BP's do/did.
If you are the ONLY one manufacturing air filled tires when the rest still produces massive rubber tires then you need only very little effort toward the car manufacturers to tell them the advantage of air filled tires and they'll roll out there cars with them to compete with the others.
That is completely different if plenty may make air filled tires, then you have competition. But Bavi is the only upstream and only PS binding substance. So BP's need it to remain or become SOC for their products.
AND more importantly in Bavi's PS world there is no place for other tires soon! Whatever other substance one would use to try the compete with Bavi it will ALWAYS have to come down to keep PS to not connect to the MDSCs and Macrophages receptors and that would be either involve targeting Bavi or targeting the receptor. And since receptors are poly-sockets and bind depending in their in-cell chemical programming of the moment, that last thing is not an option because it would disable the MDSCs and Macrophages receptors for other use.
Phil Thorpe just chose the right substance, the one that is never found outside the cell unless it get exposed and then gets another function as signalling agent.
And THOSE type of substances will be FEW.
This being said, there will of course be some marketing cost. Conventions, Presentations, papers and spreading the word in all possible ways but very probably not the door to door REP doctor visiting, samples distribution, and "try it" stuff.
If patients hear about the effects of bavi and winning treatments they automatic look for those ones.
News 
Market Data 
Discover 
AI
